The ability of PP2A to antagonise cancer development has first been suggested in the late 1980s when it was described as target of the tumour promoter okadaic acid; however, only recently, PP2A received the designation of ‘tumour suppressor’ (Van Hoof and Goris, 2004; Janssens et al, 2005). The gene discussed is PTPA; the disease is neoplasm.